$AVR

Knight Susan Elizabeth purchased $102K of AVR

Knight Susan Elizabeth purchased 11,000 shares of Anteris Technologies Global Corp. (AVR) at $9.29 ($0.10M total) on 2026-06-02.

Original reporting
SEC EDGAR · Knight Susan Elizabeth
Published Jun 4, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Bullish
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRBullishLow
01

Why it matters

The transaction may be interpreted as confidence in the stock, but it does not change fundamentals on its own without additional company-specific news.

02

Market read

Traders may use the buy as a small sentiment input, but it is unlikely to be a standalone driver of price action.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on prior holdings, motivation, or whether other insiders are buying/selling.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-04; reflects purchase dated 2026-06-02.

Background

The article is an SEC Form 4 disclosure of an insider’s open-market purchase by a director.

Company-level read

Ticker impact

$AVRBullishMedium confidence
Context

Director Susan Elizabeth Knight bought 11,000 shares of Anteris Technologies Global Corp. at $9.2935/share via open-market purchase.

Expected impact

Likely limited/short-lived price impact; may slightly improve near-term sentiment rather than drive a trend.

Evidence & confidence

The filing is a Form 4 insider transaction with a disclosed buy price and size, but no accompanying corporate event (earnings, guidance, deal, or regulatory action) is mentioned.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (e.g., diversification, compensation-related liquidity) and may not signal near-term upside.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider purchase disclosure (AVR).

  • Susan Elizabeth Knight

    Director who purchased 11,000 shares on 2026-06-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.